Studies have shown that cDC1-deficient mice display impaired immune responses to tumors and significantly reduced therapeutic efficacy of T cell-mediated tumor immunotherapies, including immune checkpoint blockade (ICB) therapy [8,9]. The gene discussed is MPPE1; the disease is neoplasm.